CA-125 in ovarian cancer: Relation between half-life, doubling time and survival
- 1 August 1991
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (8), 993-995
- https://doi.org/10.1016/0277-5379(91)90266-g
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Risks and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysisEuropean Journal of Cancer and Clinical Oncology, 1990
- Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinomaGynecologic Oncology, 1989
- Use of CA 125 to monitor patients with ovarian epithelial carcinomasGynecologic Oncology, 1989
- Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operationEuropean Journal of Cancer and Clinical Oncology, 1988
- Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovaryGynecologic Oncology, 1988
- Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapyGynecologic Oncology, 1988
- The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapyEuropean Journal of Cancer and Clinical Oncology, 1987
- CA-125 in gynecological malignanciesEuropean Journal of Cancer and Clinical Oncology, 1987
- Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second‐look operations and their role in the detection of tumour recurrenceBJOG: An International Journal of Obstetrics and Gynaecology, 1987
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983